Corporis Medical closes €4M series B financing round.
Funding will allow the company to finance its clinical trial program and complete its regulatory filings. 

Maastricht, 7 December 2023

Corporis Medical completed an all equity financing round, including the conversion of existing convertible loans. The round was led by Unorthodox Ventures, a venture capital firm based in Austin, Texas, with participation from existing investors, including Brightlands Venture Partners and LIOF.

Corporis Medical focuses on the development and commercialization of innovative medical devices for minimally invasive surgery. Proceeds will be used to fund a Randomized Controlled Trial for Mediclose™, as well as clinical validation of the fully integrated Laprixa™ System. “We are pleased that Unorthodox Ventures and our current stakeholders have shown unwavering confidence in our products that improve outcomes of surgical interventions. This round of funding will allow us to take important steps necessary to enable a market launch” said John Marugg, Chief Executive Officer of Corporis Medical.

About Corporis Medical

Corporis Medical is a MedTech company developing innovative surgical tools to improve wound healing during laparoscopic surgery, located on the Brightlands Maastricht Health Campus. Its product portfolio includes the Mediclose™ System and Laprixa™ System. The Mediclose™ System is an automatic trocar closure system to improve trocar induced wound closure. The Laprixa™ System is the world’s smallest tissue blood pressure measuring system that provides the surgeon with a quantitative, objective and patient-specific intraoperative prediction of the wound healing capacity. The company is at various stages of regulatory and clinical validation review processes while preparing for market launch.

For more information about Corporis Medical visit www.corporis-medical.com